i-Lumen Scientific develops the i-LUMEN™ system, a non-invasive medical device that employs proprietary pulsed microcurrent stimulation to treat dry age-related macular degeneration (dAMD). This therapy addresses the significant unmet need for effective treatment options in a condition that currently has no approved therapies in the U.S. market.
Funding
$18.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dry age-related macular degeneration (dAMD) is a debilitating visual disease with no cure, and currently no approved treatments available in the U.S. This lack of effective therapies leaves a significant unmet need for patients suffering from vision impairment due to dAMD.
Solution
i-Lumen Scientific offers the i-LUMEN™ system, a non-invasive medical device designed to improve eyesight in patients with dAMD. The i-LUMEN™ system utilizes proprietary pulsed microcurrent stimulation delivered via a software-based device. This therapy aims to address the unmet need for effective treatment options for dAMD.
Target Audience
The primary target audience includes ophthalmologists and patients diagnosed with dry age-related macular degeneration (dAMD) seeking a non-invasive treatment option.
Features
- Non-invasive delivery of pulsed microcurrent stimulation.
- Software-controlled medical device for precise therapy administration.
- Designed specifically for the treatment of nonexudative (dry) age-related macular degeneration (dAMD).